Finerenone, a non-steroidal mineralocorticoid receptor antagonist, faces competition from existing treatments for chronic kidney disease (CKD) associated with type 2 diabetes [1]. Bardoxolone methyl was previously developed for this indication, but its development was discontinued due to safety concerns [1].
What other drugs are used for kidney disease in type 2 diabetes?
Beyond finerenone, standard care for diabetic kidney disease includes managing blood pressure with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) [1]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors also play a significant role in managing this condition [1].
When does finerenone's patent expire?
The patent landscape for finerenone is complex, with multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes [2]. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiration dates, which is crucial for understanding potential market entry for generics or biosimilars [2].
How does finerenone work?
Finerenone works by blocking the overactivation of the mineralocorticoid receptor. This overactivation can lead to inflammation and fibrosis in the kidneys, contributing to the progression of kidney disease [1]. By inhibiting this pathway, finerenone aims to reduce these harmful effects [1].
What are the risks associated with finerenone?
Finerenone can increase potassium levels in the blood, a condition known as hyperkalemia, which may require monitoring and dose adjustments [1]. Other potential side effects include a decrease in blood pressure (hypotension) [1].
What clinical data supports finerenone's use?
Clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies, have demonstrated finerenone's ability to reduce the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes [1].
Who makes finerenone?
Finerenone is manufactured by Bayer [3].
What are the latest developments in treating diabetic kidney disease?
Research continues to explore new therapeutic targets for diabetic kidney disease. Beyond finerenone and SGLT2 inhibitors, other drug classes are under investigation to further improve outcomes for patients [1].
Sources
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] Bayer